Floatz logo

Epirubicin

Acral Lentiginous Melanoma

ECOG-ACRIN Cancer Research GroupPhase 2Active
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Acral Lentiginous Melanoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Yonsei University
Phase 2BB
Cyclophosphamide
Anusha Kalbasi
Phase 2B
Nivolumab
Fred Hutchinson Cancer Center
Phase 2B
Ipilimumab
Emory University
Phase 2B
Encorafenib
SWOG Cancer Research Network
Phase 2CCC

View all 9 →

Same molecule, other indications

Epirubicin is also rated in:

Recurrent Breast CarcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Lung Non-Small Cell Squamous CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →